Abstract：Objective：To observe the clinical effect of Fuzheng Jiedu Zengxiao prescription combined with epidermal growth factor receptor(EGFR) - tyrosine kinase inhibitor(TKI) in targeted treatment of nonsmall cell lung cancer and its effects on the expression of EGFR and autophagy effector protein(Beclin- 1). Methods：A total of 96 cases of patients with non-small cell lung cancer were divided into the control group and the study group according to the random number table method， with 48 cases in each group. Both groups were treated with EGFR-TKI targeted medicines，and the study group was additionally treated with Fuzheng Jiedu Zengxiao prescription. Both groups were treated for two months. The clinical effects and progression free survival(PFS) were compared between the two groups. The Chinese medicine syndrome scores and the content of serum tumor markers were compared between the two groups before and after treatment. The positive expression rates of EGFR and Beclin- 1 and the occurrence of adverse reactions were compared between the two groups. Results： The disease control rate(DCR) and objective effective rate(ORR) in the study group were higher than those in the control group(P＜0.05)，and the clinical effect was better than that in the control group(P＜0.05). After treatment，Chinese medicine syndrome scores of cough and weakness，poor appetite，shortness of breath and lassitude of spirit and lack of strength，and the contents of serum carcinoembryonic antigen(CEA) and cytokeratin 19 fragment(Cyfra21- 1) in the two groups were decreased when compared with those before treatment(P＜0.05)，and the above indexes in the study group were lower than those in the control group(P＜0.05). The positive expression rates of EGFR and Beclin-1 in the study group were lower than those in the control group(P＜0.05)，and PFS was longer than that in the control group(P＜0.05). The incidence of rash and diarrhea in the study group was lower than that in the control group(P＜0.05). There was no significant difference being found in the comparison of the incidence of liver and kidney dysfunction and oral mucositis between the two groups(P＞0.05). Conclusion： Fuzheng Jiedu Zengxiao prescription combined with EGFR -TKI has a defined curative effect in the targeted treatment of on-small cell lung cancer，and can prolong the disease-free survival，decrease the content of tumor markers，inhibit the expression of EGFR and Beclin-1，and reduce the occurrence of adverse drug reactions.